Technical Analysis for FRTX - Fresh Tracks Therapeutics
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.83% | |
NR7 | Range Contraction | 0.83% | |
Narrow Range Bar | Range Contraction | 0.83% | |
Inside Day | Range Contraction | 0.83% | |
Gapped Up | Strength | 0.83% | |
50 DMA Resistance | Bearish | 3.11% | |
Fell Below 20 DMA | Bearish | 3.11% | |
Expansion Pivot Sell Setup | Bearish Swing Setup | 3.11% |
Alert | Time |
---|---|
Rose Above 10 DMA | about 20 hours ago |
Possible NR7 | 1 day ago |
Possible Inside Day | 1 day ago |
Gap Up Partially Closed | 2 days ago |
Gapped Up (Partial) | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: 05/08/2024
Fresh Tracks Therapeutics Description
Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics. The Company’s pipeline aims to disrupt existing treatment paradigms and features several new molecular entities that inhibit novel targets with first-in-class potential for autoimmune, inflammatory, and other debilitating diseases. Fresh Track Therapeutic’s executive management team and board of directors have a proven track record of leadership across early-stage research, product development, and global commercialization, having served in leadership roles at large global pharmaceutical and biotech companies that successfully developed and/or launched first-in-class products that achieved iconic status, including Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta®, Juvederm®, Pluvicto®, and Sofpironium Bromide. The Company’s strategy is to align this experience and clear vision to explore beyond the limitations of current therapies by identifying, pursuing, and developing next-generation therapeutics that can be groundbreaking in their ability to help millions of people struggling with autoimmune, inflammatory, and other debilitating diseases.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Pharmaceutical Disease Inflammatory
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.1 |
52 Week Low | 0.4495 |
Average Volume | 15,070 |
200-Day Moving Average | 0.85 |
50-Day Moving Average | 0.92 |
20-Day Moving Average | 0.90 |
10-Day Moving Average | 0.90 |
Average True Range | 0.02 |
RSI (14) | 50.25 |
ADX | 13.06 |
+DI | 28.70 |
-DI | 25.00 |
Chandelier Exit (Long, 3 ATRs) | 0.88 |
Chandelier Exit (Short, 3 ATRs) | 0.93 |
Upper Bollinger Bands | 0.93 |
Lower Bollinger Band | 0.87 |
Percent B (%b) | 0.61 |
BandWidth | 6.73 |
MACD Line | -0.01 |
MACD Signal Line | -0.01 |
MACD Histogram | 0.0018 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.92 | ||||
Resistance 3 (R3) | 0.92 | 0.91 | 0.92 | ||
Resistance 2 (R2) | 0.91 | 0.91 | 0.91 | 0.92 | |
Resistance 1 (R1) | 0.91 | 0.91 | 0.91 | 0.91 | 0.92 |
Pivot Point | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 |
Support 1 (S1) | 0.90 | 0.90 | 0.90 | 0.90 | 0.90 |
Support 2 (S2) | 0.90 | 0.90 | 0.90 | 0.90 | |
Support 3 (S3) | 0.90 | 0.90 | 0.90 | ||
Support 4 (S4) | 0.90 |